Harpoon Therapeutics
Presence
Harpoon Therapeutics is a company listed under the stock ticker HARP (US).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Harpoon Therapeutics
- Julie Eastland, Director and Chief Executive Officer
- Mark Chin, Director
- Scott Myers, Chairman of the Board
Popular executive movements at Harpoon Therapeutics
- Wendy Chang, who was Senior Vice President, Human Resources, is promoted to Chief People Officer (posted on December 27 2023).
- James Bucher has joined the company as Chief Legal Officer (posted on December 27 2023).
Create your alert
to follow the executive moves at Harpoon Therapeutics.
Biotechnology
Harpoon Therapeutics has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Harpoon Therapeutics
- Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Announces Changes to Board of Directors | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Appoints Two New Members to Its Board of Directors | Harpoon Therapeutics, Inc.
- View more press releases Close
Social media about Harpoon Therapeutics
- Harpoon Therapeutics on Wikipedia, Google News & Yahoo Finance
- Harpoon Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Julie Eastland 
Call Harpoon Therapeutics at +1 650...
